A novel approach to cancer immunotherapy: Tumor cells decorated with CD80 generate effective antitumor immunity

Cancer Research

Volumn 63, Issue 14, 2003, Pages 4067-4073

  Singh, Narendra P ^a   Yolcu, Esma S ^a   Taylor, Douglas D ^b   Gercel Taylor, Cicek ^b   Metzinger, Daniel S ^b   Dreisbach, Stephen K ^a   Shirwan, Haval ^a,b  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; STREPTAVIDIN;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOTINYLATION; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DNA MODIFICATION; GYNECOLOGIC CANCER; LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE; TUMOR IMMUNITY; WESTERN BLOTTING;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; BIOTIN; FEMALE; GENE TRANSFER TECHNIQUES; GENITAL NEOPLASMS, FEMALE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; RABBITS; RECOMBINANT FUSION PROTEINS; STREPTAVIDIN; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0042173122     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Rosenberg, S. A. Progress in human tumour immunology and immunotherapy. Nature (Lond.), 411: 380-384, 2001.
2. Greenberg, P. D. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281-355, 1991.
3. Martin-Fontecha, A., Moro, M., Crosti, M. C., Veglia, F., Casorati, G., and Dellabona, P. Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity. J. Immunol., 164: 698-704, 2000.
4. Schwartz, R. H. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB 1 in interleukin-2 production and immunotherapy. Cell, 71: 1065-1068, 1992.
5. Lamb, J. R., and Feldmann, M. Essential requirement for major histocompatibility complex recognition in T-cell tolerance induction. Nature (Lond.), 308: 72-74, 1984.
6. Jenkins, M. K., and Schwartz, R. H. Antigen presentation by chemically modified splenocytes induces antigen-specific T-cell unresponsiveness in vitro and in vivo. J. Exp. Med., 165: 302-319, 1987.
7. Gilligan, M. G., Knox, P., Weedon, S., Barton, R., Kerr, D. J., Searle, P., and Young, L. S. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther., 5: 965-974, 1998.
8. Lang, S., Atarashi, Y., Nishioka, Y., Stanson, J., Meidenbauer, N., and Whiteside, T. L. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death. Cell Immunol., 201: 132-143, 2000.
9. Sumimoto, H., Tani, K., Nakazaki, Y., Tanabe, T., Hibino, H., Hamada, H., Azuma, M., and Asano, S. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice. Int. J. Cancer, 73: 556-561, 1997.
10. Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., and Ledbetter, J. A. Binding of the B-cell activation antigen B7 to CD28 costimulates T-cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med., 173: 721-730, 1991.
11. Armitage, R. J., Fanslow, W. C., Strockbine, L., Sato, T. A., Clifford, K. N., Macduff, B. M., Anderson, D. M., Gimpel, S. D., Davis-Smith, T., Maliszewski, C. R., et al. Molecular and biological characterization of a murine ligand for CD40. Nature (Lond.), 357: 80-82, 1992.
12. Horig, H., Lee, D. S., Conkright, W., Divito, J., Hasson, H., LaMare, M., Rivera, A., Park, D., Tine, J., Guito, K., Tsang, K. W., Schlom, J., and Kaufman, H. L. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother., 49: 504-514, 2000.
13. Guinn, B. A., DeBenedette, M. A., Watts, T. H., and Berinstein, N. L. 4-1BBL cooperates with B7-1 and B7-2 in converting a B-cell lymphoma cell line into a long-lasting antitumor vaccine. J. Immunol., 162: 5003-5010, 1999.
14. Antonia, S. J., Seigne, J., Diaz, J., Muro-Cacho, C., Extermann, M., Farmelo, M. J., Friberg, M., Alsarraj, M., Mahany, J. J., Pow-Sang, J., Cantor, A., and Janssen, W. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol., 167: 1995-2000, 2002.
15. Briones, J., Timmerman, J. M., Panicalli, D. L., and Levy, R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J. Natl. Cancer Inst. (Bethesda), 95: 548-555, 2003.
16. Brown, M. D., Schatzlein, A. G., and Uchegbu, I. F. Gene delivery with synthetic (nonviral) carriers. Int. J. Pharm., 229: 1-21, 2001.
17. Li, S., and Huang, L. Nonviral gene therapy: promises and challenges. Gene Ther., 7: 31-34, 2000.
18. Philip, R., Clary, B., Brunette, E., Kilinski, L., Murugesh, D., Sorich, M., Yau, J., Lebkowski, J., Lyerly, H. K., and Philip, M. Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin. Cancer Res., 2: 59-68, 1996.
19. Tolba, K. A., Bowers, W. J., Hilchey, S. P., Halterman, M. W., Howard, D. F., Giuliano, R. E., Federoff, H. J., and Rosenblatt, J. D. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood, 98: 297-295, 2001.
20. Pfeifer, A., and Verma, I. M. Gene therapy: promises and problems. Annu. Rev. Genom. Hum. Genet., 2: 177-211, 2001.
21. Galanis, E., Vile, R., and Russell, S. J. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. Crit. Rev. Oncol. Hematol., 38: 177-192, 2001.
22. Hodge, J. W., and Schlom, J. Comparative studies of a retrovirus versus a poxvirus vector in whole tumor-cell vaccines. Cancer Res., 59: 5106-5111, 1999.
23. Reznik, G. O., Vajda, S., Sano, T., and Cantor, C. R. A streptavidin mutant with altered ligand-binding specificity. Proc. Natl. Acad. Sci. USA, 95: 13525-13530, 1998.
24. Sano, T., Vajda, S., Smith, C. L., and Cantor, C. R. Engineering subunit association of multisubunit proteins: a dimeric streptavidin. Proc. Natl. Acad. Sci. USA, 94: 6153-6158, 1997.
25. Green, N. M. Avidin and streptavidin. Methods Enzymol., 184: 51-67, 1990.
26. Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., and Dustin, M. L. The immunological synapse: a molecular machine controlling T-cell activation. Science (Wash. DC), 285: 221-227, 1999.
27. Yolcu, E. S., Askenasy, N., Singh, N. P., Cherradi, S. E., and Shirwan, H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity, 17: 795-808, 2002.
28. Matzinger, P. The JAM test. A simple assay for DNA fragmentation and cell death. J. Immunol. Methods, 145: 185-192, 1991.
29. Freeman, G. J., Freedman, A. S., Segil, J. M., Lee, G., Whitman, J. F., and Nadler, L. M. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J. Immunol., 143: 2714-2722, 1989.
30. Shirwan, H., Barwari, L., and Cramer, D. V. Rejection of cardiac allografts by T cells expressing a restricted repertoire of T-cell receptor V-β genes. Immunology, 90: 572-578, 1997.
31. Marti, W. R., Zajac, P., Spagnoli, G., Heberer, M., and Oertli, D. Nonreplicating recombinant vaccinia virus encoding human B-7 molecules elicits effective costimulation of naive and memory CD4+ T lymphocytes in vitro. Cell Immunol., 179: 146-152, 1997.
32. Felzmann, T., Ramsey, W. J., and Blaese, R. M. Anti-tumor immunity generated by tumor cells engineered to express B7-1 via retroviral or adenoviral gene transfer. Cancer Lett., 135: 1-10, 1999.
33. Felzmann, T., Ramsey, W. J., and Blaese, R. M. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6, or B7-1. Gene Ther., 4: 1322-1329, 1997.
34. Chen, A., Zheng, G., and Tykocinski, M. L. Hierarchical costimulator thresholds for distinct immune responses: application of a novel two-step Fc fusion protein transfer method. J. Immunol., 164: 705-711, 2000.
35. McHugh, R. S., Ahmed, S. N., Wang, Y. C., Sell, K. W., and Selvaraj, P. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc. Natl. Acad. Sci. USA, 92: 8059-8063, 1995.
36. Wahlsten, J. L., Mills, C. D., and Ramakrishnan, S. Antitumor response elicited by a superantigen-transmembrane sequence fusion protein anchored onto tumor cells. J. Immunol., 161: 6761-6767, 1998.
37. Zhang, F., Schmidt, W. G., Hou, Y., Williams, A. F., and Jacobson, K. Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. Proc. Natl. Acad. Sci. USA, 89: 5231-5235, 1992.
38. Schendel, D. J., Frankenberger, B., Jantzer, P., Cayeux, S., Nobetaner, E., Willimsky, G., Maget, B., Pohla, H., and Blankenstein, T. Expression of B7.1 (CD80) in a renal cell carcinoma line allows expansion of tumor-associated cytotoxic T lymphocytes in the presence of an alloresponse. Gene Ther., 7: 2007-2014, 2000.
39. Mazzocchi, A., Melani, C., Rivoltini, L., Castelli, C., Del Vecchio, M., Lombardo, C., Colombo, M. P., and Parmiani, G. Simultaneous transduction of B7-1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol. Immunother., 50: 199-211, 2001.
40. Boxhorn, H. K., Smith, J. G., Chang, Y. J., Guerry, D., Lee, W. M., Rodeck, U., Turka, L. A., and Eck, S. L. Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors. Cancer Immunol. Immunother., 46: 283-292, 1998.